InflaRx N.V. (IFRX) 10-Year Financial Performance & Capital Metrics

IFRX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Show more

Revenue $166K +162.8%
EBITDA -$53M -18.5%
Net Income -$46M -8.0%
EPS (Diluted) -0.78
Gross Margin -1900.76% -155.6%
EBITDA Margin -31681.08% +54.9%
Operating Margin -31973.69% +55.1%
Net Margin -27784.96% +58.9%
ROE -56.18% -25.7%
ROIC -59% -44.0%
Debt/Equity 0.01 +20.1%
Interest Coverage -2566.39 -103.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-62.71%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM29.5%

EPS CAGR

10Y-

5Y-

3Y-

TTM36.79%

ROCE

10Y Avg-53.82%

5Y Avg-54.01%

3Y Avg-55.68%

Latest-64.17%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	231K	0	0	0	0	0	63.09K	165.79K
Revenue Growth %	-	-	-	-1%	-	-	-	-	-	1.63%
Cost of Goods Sold+	40.83K	35.66K	66.69K	179.57K	742.25K	812.47K	791.26K	627.01K	532.26K	3.32M
COGS % of Revenue	-	-	0.29%	-	-	-	-	-	8.44%	20.01%
Gross Profit+	-40.83K	-35.66K	164.31K	-179.57K	-742.25K	-812.47K	-791.26K	-627.01K	-469.17K	-3.15M
Gross Margin %	-	-	0.71%	-	-	-	-	-	-7.44%	-19.01%
Gross Profit Growth %	-	0.13%	5.61%	-2.09%	-3.13%	-0.09%	0.03%	0.21%	0.25%	-5.72%
Operating Expenses+	3.78M	6.89M	19.45M	37.52M	63.15M	38.12M	55.57M	54.44M	44.44M	49.86M
OpEx % of Revenue	-	-	84.18%	-	-	-	-	-	704.38%	300.73%
Selling, General & Admin	438K	1.84M	5.14M	12.79M	13.43M	9.02M	13.51M	15.07M	16.12M	19.33M
SG&A % of Revenue	-	-	22.24%	-	-	-	-	-	255.55%	116.57%
Research & Development	3.48M	5.28M	14.41M	25.03M	49.72M	29.1M	42.05M	39.37M	41.02M	35.36M
R&D % of Revenue	-	-	62.4%	-	-	-	-	-	650.26%	213.31%
Other Operating Expenses	-134K	-236K	-107K	-299K	0	0	0	0	-12.71M	-4.83M
Operating Income+	-3.78M	-6.89M	-19.45M	-37.52M	-63.89M	-38.93M	-56.36M	-55.07M	-44.91M	-53.01M
Operating Margin %	-	-	-84.18%	-	-	-	-	-	-711.82%	-319.74%
Operating Income Growth %	-	-0.82%	-1.82%	-0.93%	-0.7%	0.39%	-0.45%	0.02%	0.18%	-0.18%
EBITDA+	-3.74M	-6.86M	-19.38M	-37.34M	-63.15M	-38.12M	-55.57M	-54.44M	-44.34M	-52.52M
EBITDA Margin %	-	-	-83.89%	-	-	-	-	-	-702.82%	-316.81%
EBITDA Growth %	-	-0.83%	-1.83%	-0.93%	-0.69%	0.4%	-0.46%	0.02%	0.19%	-0.18%
D&A (Non-Cash Add-back)	40K	35.66K	66.69K	179.57K	742.25K	812.47K	791.26K	627.01K	567.78K	485.11K
EBIT	-3.73M	-7.1M	-22.01M	0	-59.58M	-38.71M	-53.9M	-30.94M	-42.63M	-46.04M
Net Interest Income+	-1.05M	-1.83M	-2.1M	0	2.82M	861.7K	84.62K	563.43K	3.77M	3.18M
Interest Income	5K	1K	130K	2.18M	2.84M	887.7K	109.39K	608.68K	3.8M	3.2M
Interest Expense	1.06M	1.84M	2.23M	0	22.2K	26K	24.77K	45.25K	35.63K	20.66K
Other Income/Expense	-1.14M	-2.05M	-4.79M	7.7M	4.28M	191.21K	2.43M	24.08M	2.24M	6.95M
Pretax Income+	-4.92M	-8.94M	-24.24M	-29.81M	-59.61M	-38.74M	-53.93M	-30.99M	-42.67M	-46.06M
Pretax Margin %	-	-	-104.93%	-	-	-	-	-	-676.31%	-277.82%
Income Tax+	0	0	0	7.7M	0	0	0	0	0	5.22K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.92M	-8.94M	-24.24M	-29.82M	-59.61M	-38.74M	-53.93M	-30.99M	-42.67M	-46.06M
Net Margin %	-	-	-104.93%	-	-	-	-	-	-676.31%	-277.85%
Net Income Growth %	-	-0.82%	-1.71%	-0.23%	-1%	0.35%	-0.39%	0.43%	-0.38%	-0.08%
Net Income (Continuing)	-4.92M	-8.94M	-24.24M	-29.82M	-59.61M	-38.74M	-53.93M	-30.99M	-42.67M	-46.06M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.21	-0.38	-1.03	-1.19	-1.91	-1.26	-1.10	-0.61	-0.78	-0.78
EPS Growth %	-	-0.81%	-1.71%	-0.16%	-0.61%	0.34%	0.13%	0.45%	-0.28%	0%
EPS (Basic)	-0.21	-0.38	-1.03	-1.19	-1.91	-1.26	-1.10	-0.61	-0.78	-0.78
Diluted Shares Outstanding	23.41M	23.41M	23.61M	25.1M	26M	27.06M	41.63M	44.21M	54.94M	58.92M
Basic Shares Outstanding	23.41M	23.41M	23.61M	25.09M	26M	27.06M	41.63M	44.21M	54.94M	58.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.47M	29.38M	123.98M	158.16M	118.99M	86.28M	95.68M	97.41M	109.47M	71.66M
Cash & Short-Term Investments	3.3M	29.12M	123.28M	156.57M	115.49M	81.13M	83.41M	81.81M	12.77M	18.38M
Cash Only	3.3M	29.12M	123.28M	55.39M	33.13M	25.97M	26.25M	16.27M	12.77M	18.38M
Short-Term Investments	0	0	0	101.18M	82.35M	55.16M	57.16M	65.54M	0	0
Accounts Receivable	128K	0	120K	0	0	0	1.28M	1.43M	0	0
Days Sales Outstanding	-	-	189.61	-	-	-	-	-	-	-
Inventory	28K	31K	504K	0	0	0	0	0	11.37M	6.9M
Days Inventory Outstanding	250.29	317.32	2.76K	-	-	-	-	-	7.8K	759
Other Current Assets	11K	13K	73K	541.42K	1.33M	3.86M	0	2.55M	85.06M	46.03M
Total Non-Current Assets+	117K	137K	234K	1.05M	2.59M	1.93M	29.46M	4.99M	10.74M	4.36M
Property, Plant & Equipment	109K	131K	173K	625K	1.41M	954.96K	1.68M	1.64M	1.36M	1.01M
Fixed Asset Turnover	-	-	1.34x	-	-	-	-	-	0.05x	0.16x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	7K	5K	41K	223K	452.4K	350.18K	235.22K	138.91K	42.84K	7.26K
Long-Term Investments	1K	1K	20K	207K	272.61K	272.27K	27.21M	2.9M	9.05M	3.09M
Other Non-Current Assets	0	0	193K	0	452.22K	353.52K	336.57K	308.07K	283.25K	247.75K
Total Assets+	3.59M	29.52M	124.21M	159.21M	121.58M	88.22M	125.14M	102.4M	120.21M	76.02M
Asset Turnover	-	-	0.00x	-	-	-	-	-	0.00x	0.00x
Asset Growth %	-	7.23%	3.21%	0.28%	-0.24%	-0.27%	0.42%	-0.18%	0.17%	-0.37%
Total Current Liabilities+	436K	1.75M	4.77M	7.76M	14.06M	10.1M	18.76M	13.03M	16.84M	14.17M
Accounts Payable	370K	1.53M	4.47M	6.66M	12.41M	1.74M	1.69M	4.99M	5.1M	3.41M
Days Payables Outstanding	3.31K	15.7K	24.46K	13.53K	6.1K	782.25	777.29	2.9K	3.5K	375.57
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	15K	0	0	0	1000K	1000K	0	0
Other Current Liabilities	66K	212K	298K	1.1M	1.13M	132.73K	1.52M	-1.96M	2.89M	301.54K
Current Ratio	7.96x	16.83x	26.01x	20.39x	8.46x	8.54x	5.10x	7.48x	6.50x	5.06x
Quick Ratio	7.89x	16.81x	25.90x	20.39x	8.46x	8.54x	5.10x	7.48x	5.82x	4.57x
Cash Conversion Cycle	-	-	-21.51K	-	-	-	-	-	-	-
Total Non-Current Liabilities+	20.77M	53.46M	17K	67K	369.76K	253.85K	1.1M	1.02M	782.59K	435.94K
Long-Term Debt	20.74M	53.44M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	330.75K	220.53K	1.07M	987.31K	745.72K	399.07K
Deferred Tax Liabilities	-20.74M	-53.44M	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	25K	21K	2K	56K	39.01K	33.32K	35.02K	36.88K	36.88K	36.88K
Total Liabilities	21.2M	55.21M	4.78M	7.82M	14.43M	10.35M	19.86M	14.05M	17.63M	14.6M
Total Debt+	20.74M	53.44M	0	0	845.95K	559.04K	1.43M	1.36M	1.12M	805.09K
Net Debt	17.44M	24.32M	-123.28M	-55.39M	-32.29M	-25.41M	-24.82M	-14.91M	-11.65M	-17.57M
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.02x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.58x	-3.75x	-8.72x	-	-2877.94x	-1497.37x	-2275.42x	-1216.94x	-1260.47x	-2566.39x
Total Equity+	-17.62M	-25.69M	119.43M	151.39M	107.15M	77.86M	105.28M	88.35M	102.58M	61.42M
Equity Growth %	-	-0.46%	5.65%	0.27%	-0.29%	-0.27%	0.35%	-0.16%	0.16%	-0.4%
Book Value per Share	-0.75	-1.10	5.06	6.03	4.12	2.88	2.53	2.00	1.87	1.04
Total Shareholders' Equity	-17.62M	-25.69M	119.43M	151.39M	107.15M	77.86M	105.28M	88.35M	102.58M	61.42M
Common Stock	31K	31K	2.86M	3.12M	3.13M	3.39M	5.3M	5.36M	7.07M	7.12M
Retained Earnings	-18.12M	-27.05M	-51.29M	-81.11M	-134.36M	-168.35M	-213.98M	-243.46M	-286.13M	-332.19M
Treasury Stock	-350K	-350K	0	0	0	0	0	0	0	0
Accumulated OCI	816K	1.69M	167.86M	18.31M	25.14M	22.53M	30.59M	36.64M	47.43M	51.56M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.31M	-4.99M	-12.15M	-23.71M	-43.2M	-36.53M	-39.94M	-33.74M	-37.81M	-48.56M
Operating CF Margin %	-	-	-52.61%	-	-	-	-	-	-599.36%	-292.88%
Operating CF Growth %	-	-0.51%	-1.43%	-0.95%	-0.82%	0.15%	-0.09%	0.16%	-0.12%	-0.28%
Net Income	-4.92M	-8.94M	-24.24M	-29.82M	-53.25M	-33.98M	-45.63M	-29.48M	-42.67M	-46.06M
Depreciation & Amortization	40K	33K	71K	174K	663.17K	712.71K	669.43K	596.6K	567.78K	485.11K
Stock-Based Compensation	243K	868K	4.55M	12.09M	6.83M	1.12M	4.33M	6.04M	3.41M	4.07M
Deferred Taxes	5K	0	66K	-1.88M	0	927.84K	1.16M	0	0	0
Other Non-Cash Items	1.05M	1.84M	4.82M	-6.11M	4.89M	44.25K	-2M	-1.13M	-131.29K	-4.76M
Working Capital Changes	270K	1.21M	2.58M	1.83M	-2.34M	-5.35M	1.54M	-9.77M	1M	-2.28M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	-11.37M	4.47M
Change in Payables	389K	1.37M	3.09M	2.19M	0	-3.87M	316.11K	-3.52M	0	0
Cash from Investing+	-13K	-53K	-167K	-99.45M	20.34M	21.36M	-25.95M	19.36M	-17.7M	52.36M
Capital Expenditures	-13K	-53K	-149K	-806K	-594.89K	-94.19K	-37.78K	-162.39K	-81.1K	-46.87K
CapEx % of Revenue	-	-	0.65%	-	-	-	-	-	1.29%	0.28%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	1K	-808K	20.94M	-94.19K	-37.78K	19.52M	0	1
Cash from Financing+	0	30.86M	108.8M	49.64M	-294.34K	9.17M	61.58M	1.94M	52.99M	386.45K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-9.11M	-3.35M	1.68K	-232.9K	-3.2M	-47.73K	-3.12M	-323.73K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.32M	-5.05M	-12.3M	-24.52M	-43.8M	-36.62M	-39.97M	-33.91M	-37.89M	-48.6M
FCF Margin %	-	-	-53.25%	-	-	-	-	-	-600.64%	-293.17%
FCF Growth %	-	-0.52%	-1.44%	-0.99%	-0.79%	0.16%	-0.09%	0.15%	-0.12%	-0.28%
FCF per Share	-0.14	-0.22	-0.52	-0.98	-1.68	-1.35	-0.96	-0.77	-0.69	-0.82
FCF Conversion (FCF/Net Income)	0.67x	0.56x	0.50x	0.80x	0.72x	0.94x	0.74x	1.09x	0.89x	1.05x
Interest Paid	0	0	0	0	20.9K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-51.71%	-22.02%	-46.11%	-41.88%	-58.9%	-32.01%	-44.69%	-56.18%
Return on Invested Capital (ROIC)	-	-	-	-61.07%	-56.09%	-45.87%	-63.6%	-53.67%	-40.98%	-59%
Gross Margin	-	-	71.13%	-	-	-	-	-	-743.67%	-1900.76%
Net Margin	-	-	-10492.64%	-	-	-	-	-	-67630.69%	-27784.96%
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.02x	0.01x	0.01x
Interest Coverage	-3.58x	-3.75x	-8.72x	-	-2877.94x	-1497.37x	-2275.42x	-1216.94x	-1260.47x	-2566.39x
FCF Conversion	0.67x	0.56x	0.50x	0.80x	0.72x	0.94x	0.74x	1.09x	0.89x	1.05x
Revenue Growth	-	-	-	-100%	-	-	-	-	-	162.79%

Revenue by Geography

	2022
GERMANY	4.9M
GERMANY Growth	-
UNITED STATES	100K
UNITED STATES Growth	-

Frequently Asked Questions

Growth & Financials

InflaRx N.V. (IFRX) reported $0.1M in revenue for fiscal year 2024.

InflaRx N.V. (IFRX) grew revenue by 162.8% over the past year. This is strong growth.

InflaRx N.V. (IFRX) reported a net loss of $40.1M for fiscal year 2024.

Dividend & Returns

InflaRx N.V. (IFRX) has a return on equity (ROE) of -56.2%. Negative ROE indicates the company is unprofitable.

InflaRx N.V. (IFRX) had negative free cash flow of $42.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

InflaRx N.V. (IFRX) 10-Year Financial Performance & Capital Metrics

IFRX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $166K +162.8%
EBITDA -$53M -18.5%
Net Income -$46M -8.0%
EPS (Diluted) -0.78
Gross Margin -1900.76% -155.6%
EBITDA Margin -31681.08% +54.9%
Operating Margin -31973.69% +55.1%
Net Margin -27784.96% +58.9%
ROE -56.18% -25.7%
ROIC -59% -44.0%
Debt/Equity 0.01 +20.1%
Interest Coverage -2566.39 -103.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 1.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Weak momentum: RS Rating 12 (bottom 12%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-62.71%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM29.5%

EPS CAGR

10Y-

5Y-

3Y-

TTM36.79%

ROCE

10Y Avg-53.82%

5Y Avg-54.01%

3Y Avg-55.68%

Latest-64.17%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	231K	0	0	0	0	0	63.09K	165.79K
Revenue Growth %	-	-	-	-1%	-	-	-	-	-	1.63%
Cost of Goods Sold+	40.83K	35.66K	66.69K	179.57K	742.25K	812.47K	791.26K	627.01K	532.26K	3.32M
COGS % of Revenue	-	-	0.29%	-	-	-	-	-	8.44%	20.01%
Gross Profit+	-40.83K	-35.66K	164.31K	-179.57K	-742.25K	-812.47K	-791.26K	-627.01K	-469.17K	-3.15M
Gross Margin %	-	-	0.71%	-	-	-	-	-	-7.44%	-19.01%
Gross Profit Growth %	-	0.13%	5.61%	-2.09%	-3.13%	-0.09%	0.03%	0.21%	0.25%	-5.72%
Operating Expenses+	3.78M	6.89M	19.45M	37.52M	63.15M	38.12M	55.57M	54.44M	44.44M	49.86M
OpEx % of Revenue	-	-	84.18%	-	-	-	-	-	704.38%	300.73%
Selling, General & Admin	438K	1.84M	5.14M	12.79M	13.43M	9.02M	13.51M	15.07M	16.12M	19.33M
SG&A % of Revenue	-	-	22.24%	-	-	-	-	-	255.55%	116.57%
Research & Development	3.48M	5.28M	14.41M	25.03M	49.72M	29.1M	42.05M	39.37M	41.02M	35.36M
R&D % of Revenue	-	-	62.4%	-	-	-	-	-	650.26%	213.31%
Other Operating Expenses	-134K	-236K	-107K	-299K	0	0	0	0	-12.71M	-4.83M
Operating Income+	-3.78M	-6.89M	-19.45M	-37.52M	-63.89M	-38.93M	-56.36M	-55.07M	-44.91M	-53.01M
Operating Margin %	-	-	-84.18%	-	-	-	-	-	-711.82%	-319.74%
Operating Income Growth %	-	-0.82%	-1.82%	-0.93%	-0.7%	0.39%	-0.45%	0.02%	0.18%	-0.18%
EBITDA+	-3.74M	-6.86M	-19.38M	-37.34M	-63.15M	-38.12M	-55.57M	-54.44M	-44.34M	-52.52M
EBITDA Margin %	-	-	-83.89%	-	-	-	-	-	-702.82%	-316.81%
EBITDA Growth %	-	-0.83%	-1.83%	-0.93%	-0.69%	0.4%	-0.46%	0.02%	0.19%	-0.18%
D&A (Non-Cash Add-back)	40K	35.66K	66.69K	179.57K	742.25K	812.47K	791.26K	627.01K	567.78K	485.11K
EBIT	-3.73M	-7.1M	-22.01M	0	-59.58M	-38.71M	-53.9M	-30.94M	-42.63M	-46.04M
Net Interest Income+	-1.05M	-1.83M	-2.1M	0	2.82M	861.7K	84.62K	563.43K	3.77M	3.18M
Interest Income	5K	1K	130K	2.18M	2.84M	887.7K	109.39K	608.68K	3.8M	3.2M
Interest Expense	1.06M	1.84M	2.23M	0	22.2K	26K	24.77K	45.25K	35.63K	20.66K
Other Income/Expense	-1.14M	-2.05M	-4.79M	7.7M	4.28M	191.21K	2.43M	24.08M	2.24M	6.95M
Pretax Income+	-4.92M	-8.94M	-24.24M	-29.81M	-59.61M	-38.74M	-53.93M	-30.99M	-42.67M	-46.06M
Pretax Margin %	-	-	-104.93%	-	-	-	-	-	-676.31%	-277.82%
Income Tax+	0	0	0	7.7M	0	0	0	0	0	5.22K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.92M	-8.94M	-24.24M	-29.82M	-59.61M	-38.74M	-53.93M	-30.99M	-42.67M	-46.06M
Net Margin %	-	-	-104.93%	-	-	-	-	-	-676.31%	-277.85%
Net Income Growth %	-	-0.82%	-1.71%	-0.23%	-1%	0.35%	-0.39%	0.43%	-0.38%	-0.08%
Net Income (Continuing)	-4.92M	-8.94M	-24.24M	-29.82M	-59.61M	-38.74M	-53.93M	-30.99M	-42.67M	-46.06M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.21	-0.38	-1.03	-1.19	-1.91	-1.26	-1.10	-0.61	-0.78	-0.78
EPS Growth %	-	-0.81%	-1.71%	-0.16%	-0.61%	0.34%	0.13%	0.45%	-0.28%	0%
EPS (Basic)	-0.21	-0.38	-1.03	-1.19	-1.91	-1.26	-1.10	-0.61	-0.78	-0.78
Diluted Shares Outstanding	23.41M	23.41M	23.61M	25.1M	26M	27.06M	41.63M	44.21M	54.94M	58.92M
Basic Shares Outstanding	23.41M	23.41M	23.61M	25.09M	26M	27.06M	41.63M	44.21M	54.94M	58.92M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.47M	29.38M	123.98M	158.16M	118.99M	86.28M	95.68M	97.41M	109.47M	71.66M
Cash & Short-Term Investments	3.3M	29.12M	123.28M	156.57M	115.49M	81.13M	83.41M	81.81M	12.77M	18.38M
Cash Only	3.3M	29.12M	123.28M	55.39M	33.13M	25.97M	26.25M	16.27M	12.77M	18.38M
Short-Term Investments	0	0	0	101.18M	82.35M	55.16M	57.16M	65.54M	0	0
Accounts Receivable	128K	0	120K	0	0	0	1.28M	1.43M	0	0
Days Sales Outstanding	-	-	189.61	-	-	-	-	-	-	-
Inventory	28K	31K	504K	0	0	0	0	0	11.37M	6.9M
Days Inventory Outstanding	250.29	317.32	2.76K	-	-	-	-	-	7.8K	759
Other Current Assets	11K	13K	73K	541.42K	1.33M	3.86M	0	2.55M	85.06M	46.03M
Total Non-Current Assets+	117K	137K	234K	1.05M	2.59M	1.93M	29.46M	4.99M	10.74M	4.36M
Property, Plant & Equipment	109K	131K	173K	625K	1.41M	954.96K	1.68M	1.64M	1.36M	1.01M
Fixed Asset Turnover	-	-	1.34x	-	-	-	-	-	0.05x	0.16x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	7K	5K	41K	223K	452.4K	350.18K	235.22K	138.91K	42.84K	7.26K
Long-Term Investments	1K	1K	20K	207K	272.61K	272.27K	27.21M	2.9M	9.05M	3.09M
Other Non-Current Assets	0	0	193K	0	452.22K	353.52K	336.57K	308.07K	283.25K	247.75K
Total Assets+	3.59M	29.52M	124.21M	159.21M	121.58M	88.22M	125.14M	102.4M	120.21M	76.02M
Asset Turnover	-	-	0.00x	-	-	-	-	-	0.00x	0.00x
Asset Growth %	-	7.23%	3.21%	0.28%	-0.24%	-0.27%	0.42%	-0.18%	0.17%	-0.37%
Total Current Liabilities+	436K	1.75M	4.77M	7.76M	14.06M	10.1M	18.76M	13.03M	16.84M	14.17M
Accounts Payable	370K	1.53M	4.47M	6.66M	12.41M	1.74M	1.69M	4.99M	5.1M	3.41M
Days Payables Outstanding	3.31K	15.7K	24.46K	13.53K	6.1K	782.25	777.29	2.9K	3.5K	375.57
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	15K	0	0	0	1000K	1000K	0	0
Other Current Liabilities	66K	212K	298K	1.1M	1.13M	132.73K	1.52M	-1.96M	2.89M	301.54K
Current Ratio	7.96x	16.83x	26.01x	20.39x	8.46x	8.54x	5.10x	7.48x	6.50x	5.06x
Quick Ratio	7.89x	16.81x	25.90x	20.39x	8.46x	8.54x	5.10x	7.48x	5.82x	4.57x
Cash Conversion Cycle	-	-	-21.51K	-	-	-	-	-	-	-
Total Non-Current Liabilities+	20.77M	53.46M	17K	67K	369.76K	253.85K	1.1M	1.02M	782.59K	435.94K
Long-Term Debt	20.74M	53.44M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	330.75K	220.53K	1.07M	987.31K	745.72K	399.07K
Deferred Tax Liabilities	-20.74M	-53.44M	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	25K	21K	2K	56K	39.01K	33.32K	35.02K	36.88K	36.88K	36.88K
Total Liabilities	21.2M	55.21M	4.78M	7.82M	14.43M	10.35M	19.86M	14.05M	17.63M	14.6M
Total Debt+	20.74M	53.44M	0	0	845.95K	559.04K	1.43M	1.36M	1.12M	805.09K
Net Debt	17.44M	24.32M	-123.28M	-55.39M	-32.29M	-25.41M	-24.82M	-14.91M	-11.65M	-17.57M
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.02x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.58x	-3.75x	-8.72x	-	-2877.94x	-1497.37x	-2275.42x	-1216.94x	-1260.47x	-2566.39x
Total Equity+	-17.62M	-25.69M	119.43M	151.39M	107.15M	77.86M	105.28M	88.35M	102.58M	61.42M
Equity Growth %	-	-0.46%	5.65%	0.27%	-0.29%	-0.27%	0.35%	-0.16%	0.16%	-0.4%
Book Value per Share	-0.75	-1.10	5.06	6.03	4.12	2.88	2.53	2.00	1.87	1.04
Total Shareholders' Equity	-17.62M	-25.69M	119.43M	151.39M	107.15M	77.86M	105.28M	88.35M	102.58M	61.42M
Common Stock	31K	31K	2.86M	3.12M	3.13M	3.39M	5.3M	5.36M	7.07M	7.12M
Retained Earnings	-18.12M	-27.05M	-51.29M	-81.11M	-134.36M	-168.35M	-213.98M	-243.46M	-286.13M	-332.19M
Treasury Stock	-350K	-350K	0	0	0	0	0	0	0	0
Accumulated OCI	816K	1.69M	167.86M	18.31M	25.14M	22.53M	30.59M	36.64M	47.43M	51.56M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.31M	-4.99M	-12.15M	-23.71M	-43.2M	-36.53M	-39.94M	-33.74M	-37.81M	-48.56M
Operating CF Margin %	-	-	-52.61%	-	-	-	-	-	-599.36%	-292.88%
Operating CF Growth %	-	-0.51%	-1.43%	-0.95%	-0.82%	0.15%	-0.09%	0.16%	-0.12%	-0.28%
Net Income	-4.92M	-8.94M	-24.24M	-29.82M	-53.25M	-33.98M	-45.63M	-29.48M	-42.67M	-46.06M
Depreciation & Amortization	40K	33K	71K	174K	663.17K	712.71K	669.43K	596.6K	567.78K	485.11K
Stock-Based Compensation	243K	868K	4.55M	12.09M	6.83M	1.12M	4.33M	6.04M	3.41M	4.07M
Deferred Taxes	5K	0	66K	-1.88M	0	927.84K	1.16M	0	0	0
Other Non-Cash Items	1.05M	1.84M	4.82M	-6.11M	4.89M	44.25K	-2M	-1.13M	-131.29K	-4.76M
Working Capital Changes	270K	1.21M	2.58M	1.83M	-2.34M	-5.35M	1.54M	-9.77M	1M	-2.28M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	-11.37M	4.47M
Change in Payables	389K	1.37M	3.09M	2.19M	0	-3.87M	316.11K	-3.52M	0	0
Cash from Investing+	-13K	-53K	-167K	-99.45M	20.34M	21.36M	-25.95M	19.36M	-17.7M	52.36M
Capital Expenditures	-13K	-53K	-149K	-806K	-594.89K	-94.19K	-37.78K	-162.39K	-81.1K	-46.87K
CapEx % of Revenue	-	-	0.65%	-	-	-	-	-	1.29%	0.28%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	1K	-808K	20.94M	-94.19K	-37.78K	19.52M	0	1
Cash from Financing+	0	30.86M	108.8M	49.64M	-294.34K	9.17M	61.58M	1.94M	52.99M	386.45K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	-9.11M	-3.35M	1.68K	-232.9K	-3.2M	-47.73K	-3.12M	-323.73K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.32M	-5.05M	-12.3M	-24.52M	-43.8M	-36.62M	-39.97M	-33.91M	-37.89M	-48.6M
FCF Margin %	-	-	-53.25%	-	-	-	-	-	-600.64%	-293.17%
FCF Growth %	-	-0.52%	-1.44%	-0.99%	-0.79%	0.16%	-0.09%	0.15%	-0.12%	-0.28%
FCF per Share	-0.14	-0.22	-0.52	-0.98	-1.68	-1.35	-0.96	-0.77	-0.69	-0.82
FCF Conversion (FCF/Net Income)	0.67x	0.56x	0.50x	0.80x	0.72x	0.94x	0.74x	1.09x	0.89x	1.05x
Interest Paid	0	0	0	0	20.9K	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-51.71%	-22.02%	-46.11%	-41.88%	-58.9%	-32.01%	-44.69%	-56.18%
Return on Invested Capital (ROIC)	-	-	-	-61.07%	-56.09%	-45.87%	-63.6%	-53.67%	-40.98%	-59%
Gross Margin	-	-	71.13%	-	-	-	-	-	-743.67%	-1900.76%
Net Margin	-	-	-10492.64%	-	-	-	-	-	-67630.69%	-27784.96%
Debt / Equity	-	-	-	-	0.01x	0.01x	0.01x	0.02x	0.01x	0.01x
Interest Coverage	-3.58x	-3.75x	-8.72x	-	-2877.94x	-1497.37x	-2275.42x	-1216.94x	-1260.47x	-2566.39x
FCF Conversion	0.67x	0.56x	0.50x	0.80x	0.72x	0.94x	0.74x	1.09x	0.89x	1.05x
Revenue Growth	-	-	-	-100%	-	-	-	-	-	162.79%

Revenue by Geography

	2022
GERMANY	4.9M
GERMANY Growth	-
UNITED STATES	100K
UNITED STATES Growth	-

Frequently Asked Questions

Growth & Financials

InflaRx N.V. (IFRX) reported $0.1M in revenue for fiscal year 2024.

InflaRx N.V. (IFRX) grew revenue by 162.8% over the past year. This is strong growth.

InflaRx N.V. (IFRX) reported a net loss of $40.1M for fiscal year 2024.

Dividend & Returns

InflaRx N.V. (IFRX) has a return on equity (ROE) of -56.2%. Negative ROE indicates the company is unprofitable.

InflaRx N.V. (IFRX) had negative free cash flow of $42.6M in fiscal year 2024, likely due to heavy capital investments.